Sepracor and ACADIA Forge CNS Alliance
By Business Review Editor
Pharma Deals Review: Vol 2005 Issue 57 (Table of Contents)
Published: 1 Mar-2005
DOI: 10.3833/pdr.v2005.i57.708 ISSN: 1756-7874
Section: Features
Fulltext:
Abstract
Sepracor's partnership with ACADIA Pharmaceuticals, potentially worth US$95 M, has been forged to develop new drug candidates against CNS disorders, including sleep-related indications and schizophrenia...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018